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Hyperglycemic Hyperosmolar Syndrome Caused by Steroid 
Therapy in a Patient with Lupus Nephritis
A 51-yr-old female was referred to our outpatient clinic for the evaluation of generalized 
edema. She had been diagnosed with idiopathic thrombocytopenic purpura (ITP). She had 
taken no medicine. Except for the ITP, she had no history of systemic disease. She was 
diagnosed with systemic lupus erythematosus. Immunosuppressions consisting of high-
dose steroid were started. When preparing the patient for discharge, a generalized 
myoclonic seizure occurred at the 47th day of admission. At that time, the laboratory and 
neurology studies showed hyperglycemic hyperosmolar syndrome. Brain MRI and EEG 
showed brain atrophy without other lesion. The seizure stopped after the blood sugar and 
serum osmolarity declined below the upper normal limit. The patient became 
asymptomatic and she was discharged 10 weeks after admission under maintenance 
therapy with prednisolone, insulin glargine and nateglinide. The patient remained 
asymptomatic under maintenance therapy with deflazacort and without insulin or 
medication for blood sugar control.
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CASE REPORT
Nephrology
INTRODUCTION
Seizure in patients with systemic lupus erythematosus (SLE) is 
considered to be one of the major manifestations of the disease. 
The prevalence of seizure has been documented as about 10 to 
20% in the patients with SLE (1, 2). This neuropsychiatric event 
is likely to be primary to the SLE or secondary due to other con-
comitant conditions, including infection, hypertension, hyper-
lipidemia, metabolic derangement and the toxic effects of ther-
apy (3, 4). Hyperglycemic hyperosmolar syndrome (HHS) is a 
metabolic emergency, and it commonly occurs in elderly, dis-
abled people with type 2 diabetes. The report of Sament and 
Schwartz in 1957 is widely credited as the original description 
of HHS. The proposed criteria for HHS are a plasma glucose 
concentration > 33.3 mM/L, a serum carbon dioxide concen-
tration > 15 mM/L, no or mild ketonuria, absent to mild keto-
nemia, a serum osmolarity > 320 mM/kg and mental change 
(5). However, HHS without other metabolic derangement and 
that occurs in a patient with lupus nephritis without diabetes 
and who received short term steroid therapy is a very rare com-
plication.
CASE DESCRIPTION
A 51-yr-old female was referred to our outpatient clinic for the 
evaluation of generalized edema on November 17, 2009. Two 
years previously, she had been diagnosed with idiopathic throm-
bocytopenic purpura (ITP). She had taken no medicine. Except 
for the ITP, she had no history of systemic disease like diabetes 
or hypertension. On admission, her blood pressure was 140/80 
mmHg with a pulse rate of 76 beats/min. Her lower extremities 
showed pretibial pitting edema of grade 4. The patient also re-
ported foamy urine for several days.
  The chest radiography revealed cardiomegaly (the CT ratio 
was 0.54) and bilateral pleural effusions. The ECG showed nor-
mal sinus rhythm. Both kidneys showed diffusely increased pa-
renchymal echogenicity with partially obliteration of the corti-
comedullary differentiation and a normal range of size (the right 
kidney was 10.3 cm by 4.5 cm in size, and the left kidney was 9.5 
cm by 4.5 cm in size).
  The laboratory findings showed nephrotic syndrome with 
generalized edema; the 24 hr urine protein was 5.3 g/24 hr, the 
total cholesterol was 7 mM/L (normal: < 5.2 mM/L) and the se-
rum albumin was 22 g/L (normal: 35-52 g/L). On admission, 
the fasting blood glucose and hemoglobin A1C (HbA1c) were 
5.4 mM/L and 0.05 Hb fraction, respectively. The blood urea ni-
trogen and serum creatinine were 20.6 mM/L (normal: 2.6-7.3 
mM/L) and 0.23 mM/L (normal: 0.05-0.11 mM/L). In addition, 
the patient had a positive antinuclear antibody titer at 1:1,600 
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DNA at 400 IU/mL (normal: < 100 IU/mL) and she was negative 
for antiphospholipid antibodies. The complement C3 and C4 
levels were low at 0.28 g/L (normal: 0.76-1.39 g/L) and 0.073 g/L 
(normal: 0.12-0.37 g/L), respectively. She was diagnosed with 
systemic lupus erythematosus by the American College of Rheu-
matology criteria (6). At diagnosis, the SLEDAI score was 14. At 
the 6th day of admission, a renal biopsy was performed. That 
showed diffuse global glomerulonephritis with active lesion and 
IV-G(A) by the ISN/RPS classification (7).
  Immunosuppressions consisting of high-dose steroid (meth-
ylprednisolone 750 mg for 3 days followed by prednisolone 60 
mg), cyclophosphamide pulses (500 mg at the 6th and 36th day 
of admission), as well as plasma exchange were all started. In 
addition, she had oliguria that was refractory to diuretics, and 
this led us to start hemodialysis. After four session of hemodial-
ysis, the oliguria was resolved. The clinical course was compli-
cated by thrombocytopenia, which might be due to cyclophos-
phamide. The peripheral blood smear revealed normocytic nor-
mochronic anemia and thrombocytopenia without abnormal 
cells. There was no clinical evidence of infection or disease flare 
up.
  While maintaining a stable clinical course, a generalized myo-
clonic seizure occurred at the 47th day of admission. At that time, 
her body temperature was 36.1°C. The laboratory and neurolo-
gy studies showed hyperglycemic hyperosmolar syndrome with 
a blood glucose level of > 44.4 mM/L, the serum osmolarity was 
382 mM/kg (normal: 275-300 mM/kg) and the hemoglobin A1c 
was 0.082 Hb fraction. The serum pH was 7.348 and the bicar-
bonate was 26.2 mM/L (normal: 21-28 mM/L). The urine dip 
stick test was negative for ketones. The other electrolyte levels 
were within the normal limits. Brain MRI and EEG showed brain 
atrophy without other lesion. The C-reactive protein was nor-
mal at 3.9 mg/L (normal: 0.1-4.7 mg/L). The complement C3 
and C4 levels were 0.66 g/L (normal: 0.76-1.39 g/L) and 0.237 g/
L (normal: 0.12-0.37 g/L), respectively. At shortly before seizure, 
the SLEDAI score was 12. The patient was treated with insulin 
and anticonvulsant medication. The seizure stopped after the 
blood sugar and serum osmolarity declined below the upper 
normal limit mentioned above. The patient became asymptom-
atic and she was discharged 10 weeks after admission under 
maintenance therapy with prednisolone 10 mg, insulin glargine 
12 unit and nateglinide 270 mg. On follow-up 1, 2, and 3 month 
after discharge, the HbA1c was 0.051, 0.049, and 0.06 Hb frac-
tion, respectively. The changes of laboratory findings according 
to treatment are showed in Figs. 1, 2. The patient remained as-
ymptomatic under maintenance therapy with deflazacort 12 mg 
and without insulin or medication for blood sugar control.
DISCUSSION
In patients with lupus nephritis, the causes of seizure are a mul-
tiplicity of different factors, such as CNS involvement of SLE, 
P
l
a
t
e
l
e
t
 
c
o
u
n
t
 
(
×
 
1
0
9
/
L
)
S
e
r
u
m
 
c
r
e
a
t
i
n
i
n
e
 
(
m
M
/
L
)
Days
  HD 15  HD 30  HD 45   HD 60
250
200
150
100
50
0
0.6
0.5
0.4
0.3
0.2
0.1
0.0
Seizure
Steroid
MPD 750 mg/day
PD 10 mg/day PD 40 mg/day
Platelet
Creatinine
Plasma exchange every two days
Cyclophosphamide infusion
Hemodialysis
Fig. 1. Course of platelet count and creatinine levels according to treatments. HD, hospital day; MPD, methylprednisolone; PD, prednisolone.
Fig. 2. Changes of hemoglobin A1c and osmolarity according to treatment. ADM, 
admission; HD, hospital day; DC, discharge.
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infections, hypertension and metabolic derangement. A large 
prospective study reported that infection was the most common 
cause of neurologic episodes and primary involvement of SLE 
was the secondary cause (8). The presence of seizure increases 
the risk of death in patients with SLE by approximately 2-fold (2, 
9). When seizure is noted in patients with lupus nephritis, iden-
tifying the cause and proper treatment are important to improve 
survival. Most studies have revealed that reversible posterior 
leukoencephalopathy syndrome and cerebral vascular accident 
are other important causes of seizure in patients with lupus ne-
phritis. By contrast, the neurologic episodes by purely metabol-
ic derangement without infection or CNS lupus are very rare, 
and especially HHS was a seldom cause of seizure (8).
  Steroid is associated with the risk of hyperglycemia in pati-
ents with or without diabetes (10, 11). Steroid interfere at sever-
al steps in insulin signaling cascade. This inhibit insulin signal-
ling in skeletal muscle and liver, resulting in reduced glucose 
uptake and glycogen systhesis, increased breakdown of skeletal 
muscle mass, increased hepatic glucose production. In addi-
tions, steroid increase whole body lipolysis, resulting in increased 
nonesterified fatty acids (NEFA) and triglyceride (TG). Augment-
ed levels of NFEA and TG may enhance the accumulation of 
intracellular lipids, which impair glucose metabolisms and in-
duce hepatic steatosis, dyslpidemia. Steroid most likely exert 
inhibitory effects in the beta-cell after exposure, resulting de-
creased beta-cell insulin production (12-14). Diabetes develops 
in 5%-7% of the patients on steroid (15). Steroid-induced diabe-
tes improves with reducing the dose of steroid. Acute complica-
tions, like HHS or diabetic ketoacidosis, rarely develop. As an 
acute complication of diabetes, the overall mortality of HHS is 
in the range of 10%-50%. However, when therapy is promptly 
instituted, the mortality rate can be reduced. The earliest symp-
toms of marked hyperglycemia include polyuria, polydipsia and 
weight loss. As degree of hyperglycemia progresses, patients ex-
perience neurologic symptoms (5). Treatment is targeted to-
wards 1) correcting the intravascular volume and electrolyte 
derangements; 2) decreasing the hyperglycemia and hyperos-
molarity by insulin; and 3) identifying and managing the co-
morbidities triggering the HHS (5, 16).
  Althought hyperglycemia due to steroid therapy is a common, 
but acute complication of diabetes, HHS as a first manifestation 
is a very rare event. Our case showed that seizure developed due 
to HHS despite of the short-term steroid therapy. We should 
consider HHS as a cause of seizure in patient with lupus nephri-
tis and who are treated with steroid.
  In conclusion, our case highlights the importance of regular 
blood glucose testing during or before high-dose steroid therapy.
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